Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Treatment with the drug demonstrated statistically significant improvements in biochemical response compared to UDCA alone, Christelle Huguet, executive vice president and head of research and development at Ipsen, said in a press release
Mechanism of Action ARA-290 has been investigated for its selective activation of the innate repair receptor (IRR), a heterodimeric complex composed of the EPO receptor and beta common receptor (CD131)
Disease subtype matching: AMD has geographic atrophy subtype (dry) versus neovascular subtype (wet)
Verified for identity
Lancet, 2021
US$ 24.74
US$ 23.91
US$ 21.65
US$ 28.86
US$ 27.83
US$ 23.61
